DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Running, not enrolling · Phase 3
Conditions studied: Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
In brief
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
Key facts
- Study ID
- NCT06384573
- Run by
- Washington University School of Medicine
- People needed
- 40
- Starts
- 2024-06-10
- Expected to finish
- 2030-06-01
- Last updated by the study team
- 2026-07-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama in Birmingham — Birmingham, Alabama, United States
- Indiana University School of Medicine — Indianapolis, Indiana, United States
- Washington University in St. Louis — St Louis, Missouri, United States
- University of Washington — Seattle, Washington, United States
- Neuroscience Research Australia — Randwick, New South Wales, Australia
- The National Hospital for Neurology and Neurosurgery — London, Greater London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.